Breaking News

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. AstraZeneca (AZN) has reached an agreement with Europe's Inclusive Vaccines Alliance, or IVA, spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400M doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020, the company announced. "With the agreement, the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative. The IVA is committed to providing equitable access to all participating countries across Europe. AstraZeneca continues to build a number of supply chains in parallel across the world, including for Europe. The company is seeking to expand manufacturing capacity further and is open to collaborating with other companies in order to meet its commitment to support access to the vaccine at no profit during the pandemic," AstraZeneca stated. 2. Carlos Ghosn always said he was set up and now there seems to be some evidence to support his claim, Bloomberg's Reed Stevenson reported. According to people familiar with what happened and previously unreported internal correspondence, the campaign by top Nissan (NSANY) executives to dethrone one of the most celebrated leaders in the automotive industry started almost a year before Ghosn's arrest in late 2018 for alleged financial misconduct, the author noted. 3. Eating at home may not end even when COVID-related lockdowns do, which are good news for packaged-food companies, Teresa Rivas wrote in this week's edition of Barron's. Barron's previously argued that investors should buy into the group, given their valuation and ability to hold up better than other stocks through the crisis. Four of the five the publication recommended - Campbell Soup (CPB), Conagra (CAG), General Mills (GIS) and Kraft Heinz (KHC) - have outperformed the S&P500 year to date, with Kellogg (K) the only laggard. Of those, Campbell, Conagra, and General Mills remain some of the most appealing of the big packaged-food players, the author added. 4. Dr. Reddy's Laboratories (RDY) announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences (GILD) that will grant Dr. Reddy's the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy's will receive technology transfer from Gilead for manufacturing of this drug. Dr. Reddy's would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries. Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization by the U.S. Food and Drug Administration to treat COVID-19. 5. Goldman Sachs (GS), Progressive (PGR), Home Depot (HD), Johnson & Johnson (JNJ), Lam Research (LRCX), McDonald's (MCD), NextEra Energy (NEE), Procter & Gamble (PG), Roche (RHHBY), Texas Instruments (TXN), MercadoLibre (MELI) and JD.com (JD) saw positive mentions in this week's edition of Barron's.